MPS VI Clinical Surveillance Program (CSP)

Trial Profile

MPS VI Clinical Surveillance Program (CSP)

Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Galsulfase (Primary)
  • Indications Mucopolysaccharidosis VI
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MPS VI CSP
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 30 Oct 2014 New source identified and integrated: United Kingdom Clinical Research Network record.
    • 28 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top